Erica N Grodin1, Elizabeth M Burnette2, ReJoyce Green1, Aaron C Lim1, Karen Miotto3, Lara A Ray4. 1. Department of Psychology, University of California, Los Angeles, Los Angeles, CA 90095, United States. 2. Department of Psychology, University of California, Los Angeles, Los Angeles, CA 90095, United States; Neuroscience Interdepartmental Program, University of California, Los Angeles, Los Angeles, CA 90095, United States. 3. Neuroscience Interdepartmental Program, University of California, Los Angeles, Los Angeles, CA 90095, United States. 4. Department of Psychology, University of California, Los Angeles, Los Angeles, CA 90095, United States; Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA 90095, United States; Brain Research Institute, University of California, Los Angeles, Los Angeles, CA 90095, United States. Electronic address: lararay@psych.ucla.edu.
Abstract
BACKGROUND: There is a strong bidirectional relationship between the use of alcohol and cigarettes which results in various challenges for treating those who co-use both substances. While varenicline and naltrexone each have FDA-approval for nicotine and alcohol use disorder, respectively, there is evidence that their clinical benefit may extend across the two disorders. Critically, the effect of combined varenicline and naltrexone on neural reactivity to alcohol cues among heavy drinking smokers has not yet been studied. Probing the effect of the combination therapy on alcohol cue-reactivity may give insight to the mechanisms underlying its efficacy. METHODS: Forty-seven heavy drinking smokers enrolled in two medication studies were randomized to receive varenicline alone (n = 11), varenicline plus naltrexone (n = 11), or placebo (n = 25). Participants completed an fMRI alcohol cue-reactivity task and rated their in-scanner alcohol craving. Whole-brain analyses examined the effect of medication on alcohol cue-elicited neural response. RESULTS: Varenicline plus naltrexone attenuated alcohol cue-elicited activation in mesolimbic regions relative to varenicline alone and to placebo (Z > 2.3, p < 0.05). The combination varenicline and naltrexone group also endorsed lower in-scanner alcohol craving relative to varenicline alone group (p = 0.04). CONCLUSIONS: These findings provide evidence for the benefit of combined therapy of varenicline and naltrexone over varenicline alone for the attenuation of alcohol cue-elicited neural activation. This study provides a preliminary proof-of-mechanism for this combination pharmacotherapy and suggests that naltrexone may be driving the reductions in cue-elicited alcohol craving in the brain. Further clinical studies using the combined therapy to treat heavy drinking smokers are warranted.
BACKGROUND: There is a strong bidirectional relationship between the use of alcohol and cigarettes which results in various challenges for treating those who co-use both substances. While varenicline and naltrexone each have FDA-approval for nicotine and alcohol use disorder, respectively, there is evidence that their clinical benefit may extend across the two disorders. Critically, the effect of combined varenicline and naltrexone on neural reactivity to alcohol cues among heavy drinking smokers has not yet been studied. Probing the effect of the combination therapy on alcohol cue-reactivity may give insight to the mechanisms underlying its efficacy. METHODS: Forty-seven heavy drinking smokers enrolled in two medication studies were randomized to receive varenicline alone (n = 11), varenicline plus naltrexone (n = 11), or placebo (n = 25). Participants completed an fMRI alcohol cue-reactivity task and rated their in-scanner alcohol craving. Whole-brain analyses examined the effect of medication on alcohol cue-elicited neural response. RESULTS: Varenicline plus naltrexone attenuated alcohol cue-elicited activation in mesolimbic regions relative to varenicline alone and to placebo (Z > 2.3, p < 0.05). The combination varenicline and naltrexone group also endorsed lower in-scanner alcohol craving relative to varenicline alone group (p = 0.04). CONCLUSIONS: These findings provide evidence for the benefit of combined therapy of varenicline and naltrexone over varenicline alone for the attenuation of alcohol cue-elicited neural activation. This study provides a preliminary proof-of-mechanism for this combination pharmacotherapy and suggests that naltrexone may be driving the reductions in cue-elicited alcohol craving in the brain. Further clinical studies using the combined therapy to treat heavy drinking smokers are warranted.
Authors: Christopher W Kahler; Ron Borland; Andrew Hyland; Sherry A McKee; Mary E Thompson; K Michael Cummings Journal: Drug Alcohol Depend Date: 2008-12-03 Impact factor: 4.492
Authors: Jessica L Barrington-Trimis; Robert Urman; Adam M Leventhal; W James Gauderman; Tess Boley Cruz; Tamika D Gilreath; Steve Howland; Jennifer B Unger; Kiros Berhane; Jonathan M Samet; Rob McConnell Journal: Pediatrics Date: 2016-07-11 Impact factor: 7.124
Authors: Carlos Blanco; Mark Olfson; Mayumi Okuda; Edward V Nunes; Shang-Min Liu; Deborah S Hasin Journal: Drug Alcohol Depend Date: 2008-06-24 Impact factor: 4.492
Authors: Lara A Ray; Kelly E Courtney; Dara G Ghahremani; Karen Miotto; Arthur Brody; Edythe D London Journal: Am J Drug Alcohol Abuse Date: 2014-06-20 Impact factor: 3.829
Authors: Erica N Grodin; Spencer Bujarski; Brandon Towns; Elizabeth Burnette; Steven Nieto; Aaron Lim; Johnny Lin; Karen Miotto; Artha Gillis; Michael R Irwin; Christopher Evans; Lara A Ray Journal: Transl Psychiatry Date: 2021-06-12 Impact factor: 6.222